Targeted drug therapy: The platelet side

References

• Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer: Journal for Clinicians 2009; 59: 111–137
   PubMed Web of Science ®Google Scholar
• Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: New hope for successful cancer therapy. Anticancer Agents in Medicinal Chemistry 2009; 9: 66–76
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology 2009; 27: 6041–6051
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics 2006; 319: 998–1008
   PubMed Web of Science ®Google Scholar
• Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: Biology, therapeutic targets and drugs. Drug Discovery Today 2010; 15: 517–530
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B. Spleen tyrosine kinases: Biology, therapeutic targets and drugs. Rommel C, Vanhaesebroeck B, Vogt P. 2010, Current Topics in Microbiology and Immunology. Springer, Heidelberg, Dordrecht, London, New York 2010;1–19
   Google Scholar
• Ihle NT, Powis G. Take your PIK: Phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Molecule Cancer Therapeutics 2009; 8: 1–9
   PubMed Web of Science ®Google Scholar
• Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: The role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochemical Journal 1993; 296 (Pt 2): 297–301
   Google Scholar
• Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008; 27: 5511–5526
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C. PI3K inhibitors for cancer treatment: Where do we stand?. Biochemical Society Transactions 2009; 37: 265–272
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. Mechanisms of thrombus formation. The New England Journal of Medicine 2008; 359: 938–949
   PubMed Web of Science ®Google Scholar
• Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arteriosclerosis, Thrombosis and Vascular Biology 2008; 28: 403–412
   PubMed Web of Science ®Google Scholar
• Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, et al. G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arteriosclerosis, Thrombosis and Vascular Biology 2009; 29: 449–457
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673–1685
   PubMed Web of Science ®Google Scholar
• Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. Immunological Reviews 2007; 218: 247–264
   PubMed Web of Science ®Google Scholar
• Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, Tybulewicz VL, Watson SP. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. Embo Journal 1997; 16: 2333–2341
   PubMed Web of Science ®Google Scholar
• Watson SP. Collagen receptor signaling in platelets and megakaryocytes. Journal of Thrombosis and Haemostosis 1999; 82: 365–376
   Google Scholar
• Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. Journal of Thrombosis and Haemostasis 2005; 3: 1752–1762
   PubMed Web of Science ®Google Scholar
• Suzuki-Inoue K, Wilde JI, Andrews RK, Auger JM, Siraganian RP, Sekiya F, Rhee SG, Watson SP. Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine kinase Syk and phospholipase Cgamma2 at distinct sites. Biochemical Journal 2004; 378: 1023–1029
   PubMedGoogle Scholar
• Offermanns S. Activation of platelet function through G protein-coupled receptors. Circulation Research 2006; 99: 1293–1304
   PubMed Web of Science ®Google Scholar
• Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. Journal of Thrombosis and Haemostasis 2006; 4: 2317–2326
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends in Biochemical Sciences 1997; 22: 267–272
   PubMed Web of Science ®Google Scholar
• Anderson KE, Jackson SP. Class I phosphoinositide 3-kinases. The International Journal of Biochemistry and Cell Biology 2003; 35: 1028–1033
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Experimental Cell Research 1999; 253: 239–254
   PubMed Web of Science ®Google Scholar
• Senis YA, Atkinson BT, Pearce AC, Wonerow P, Auger JM, Okkenhaug K, Pearce W, Vigorito E, Vanhaesebroeck B, Turner M, et al. Role of the p110delta PI 3-kinase in integrin and ITAM receptor signalling in platelets. Platelets 2005; 16: 191–202
   PubMed Web of Science ®Google Scholar
• Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, Wymann M, Montrucchio G. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB Journal 2001; 15: 2019–2021
   PubMed Web of Science ®Google Scholar
• Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, et al. PI 3-kinase p110beta: A new target for antithrombotic therapy. Nature Medicine 2005; 11: 507–514
   PubMed Web of Science ®Google Scholar
• Martin V, Guillermet-Guibert J, Chicanne G, Cabou C, Jandrot-Perrus M, Plantavid M, Vanhaesebroeck B, Payrastre B, Gratacap MP. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010; 115: 2008–2013
   PubMed Web of Science ®Google Scholar
• Gilio K, Munnix IC, Mangin P, Cosemans JM, Feijge MA, van der Meijden PE, Olieslagers S, Chrzanowska-Wodnicka MB, Lillian R, Schoenwaelder S, et al. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. The Journal of Biological Chemistry 2009; 284: 33750–33762
   PubMedGoogle Scholar
• Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, Daniel JL, Kunapuli SP. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. The Journal of Biological Chemistry 2009; 284: 33763–33772
   PubMed Web of Science ®Google Scholar
• Pestina TI, Stenberg PE, Druker BJ, Steward SA, Hutson NK, Barrie RJ, Jackson CW. Identification of the Src family kinases, Lck and Fgr in platelets. Their tyrosine phosphorylation status and subcellular distribution compared with other Src family members. Arteriosclerosis, Thrombosis and Vascular Biology 1997; 17: 3278–3285
   Google Scholar
• Gratacap MP, Martin V, Valera MC, Allart S, Garcia C, Sie P, Recher C, Payrastre B. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114: 1884–1892
   PubMed Web of Science ®Google Scholar
• Reilly MP, Sinha U, Andre P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, et al. PRT- 060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse 628 model. Blood 2011;117:2241–2246
   Google Scholar
• Clark EA, Shattil SJ, Ginsberg MH, Bolen J, Brugge JS. Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha IIb beta 3. The Journal of Biological Chemistry 1994; 269: 28859–28864
   PubMed Web of Science ®Google Scholar